Showing results (1-10 of 54) with videos related to
Sort By:
Pageof 6
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 1, 2015
Pharmacovigilance Considerations for Biosimilars in the USAGustavo Grampp, Thomas FelixTherapeutic Innovation & Regulatory Science|September 19, 2018
Identifying and Quantifying the Accuracy of Product Name Attribution of US-Sourced Adverse Event Reports in MedWatch of Somatropins and InsulinsStella Stergiopoulos, Carrie A Brown, Gustavo Grampp, et al.Drug Safety|September 18, 2016
A Survey of Adverse Event Reporting Practices Among US Healthcare ProfessionalsStella Stergiopoulos, Carrie A Brown, Thomas Felix, et al.Expert Opinion on Drug Safety|January 6, 2015
Active and passive surveillance of enoxaparin generics: a case study relevant to biosimilarsGustavo Grampp, Machaon Bonafede, Thomas Felix, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 20, 2015
The Diversity of Biosimilar Design and Development: Implications for Policies and StakeholdersGustavo Grampp, Sundar RamananExpert Review of Clinical Pharmacology|January 7, 2014
Preventing shortages of biologic medicinesSundar Ramanan, Gustavo GramppNephrology News & Issues|December 19, 2015
Study design is important for ESA biosimilarsAllan Pollock, Gustavo GramppBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 26, 2014
Drift, evolution, and divergence in biologics and biosimilars manufacturingSundar Ramanan, Gustavo GramppBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 27, 2013
Managing unexpected events in the manufacturing of biologic medicinesGustavo Grampp, Sundar RamananCurrent Medical Research and Opinion|April 24, 2012
Comparability and biosimilarity: considerations for the healthcare providerJaymi F Lee, Jason B Litten, Gustavo GramppPageof 6